Roivant Q2 net loss $113.5M; brepocitinib Phase 3 DM trial succeeds on all endpoints

Roivant Sciences Ltd.

2025-Q2 EPS reported -$0.49 revenue$3,741,000

Brepocitinib 30 mg met primary and all nine key secondary endpoints in Phase 3 VALOR DM study; NDA filing planned H1 2026.
Net loss attributable to Roivant $113.5M ($0.17/sh) vs $230.2M ($0.31) a year ago; revenue $1.6M.
Cash and marketable securities $4.4B as of Sept 30, 2025; R&D spend $164.6M (up 15% YoY).
Immunovant batoclimab TED: first Phase 3 readout by end-2025, but both studies to release concurrently in H1 2026 due to competitive dynamics.
Favorable Markman ruling in Pfizer/BioNTech LNP litigation; Moderna jury trial scheduled March 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.